Japan
Also, South Korean startup Lunit obtains two new US FDA approvals for its AI diagnostic tools.
This version of the Health2Sync app is currently available in Japan.
They will develop and commercialise three novel digital therapeutic products.
Clinical research is set to verify the technology's effectiveness in estimating abnormal heart movements.
Its Bisu Body Coach provides personalised health advice through urine and saliva testing.
This collaboration will work with an unnamed pharma company in Japan to know how its drugs behave compared to rival products.
The app provides personalised treatment guidance to users based on their BP record, habit logs and behavioural changes.
The diagnostic software runs on Lunit's AI technology to spot major abnormal findings.
The three-year partnership seeks to derive insights that can be applied to Otsuka's products and other offerings.
They are also seeking ways to improve high blood pressure management.